Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma - Analysis of O6-methylguanine-DNA methyltransferase status

Journal of Neuro-Oncology

Volumn 92, Issue 2, 2009, Pages 227-232

  Nagane, Motoo ^a   Nozue, Kyoko ^a   Shimizu, Saki ^a   Waha, Andreas ^b   Miyazaki, Hiroshi ^a   Kurita, Hiroki ^a   Homori, Masashi ^a   Fujioka, Yasunori ^a   Shiokawa, Yoshiaki ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Combined radiochemotherapy; Glioblastoma; O6 methylguanine DNA methyltransferase; Pancytopenia; Temozolomide; Thrombocytopenia

Indexed keywords

LEVOFLOXACIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE;

ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; BRAIN SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MEGAKARYOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PROMOTER REGION; RADIATION DOSE FRACTIONATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; X IRRADIATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BASE SEQUENCE; BLOTTING, WESTERN; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEUROSURGICAL PROCEDURES; PANCYTOPENIA; POLYMERASE CHAIN REACTION; RADIOTHERAPY; THROMBOCYTOPENIA; TUMOR SUPPRESSOR PROTEINS;

EID: 61349104698     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9754-7     Document Type: Article

References (19)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
2. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003. doi: 10.1056/NEJMoa043331
3. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797
4. Palmisano WA, Divine KK, Saccomanno G et al (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954-5958
5. Mikeska T, Bock C, El-Maarri O et al (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368-381. doi: 10.2353/ jmoldx.2007.060167
6. Gerber DE, Grossman SA, Zeltzman M et al (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-oncology 9:47-52. doi: 10.1215/ 15228517-2006-024
7. Singhal N, Selva-Nayagam S, Brown MP (2007) Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment - case study and review of literature. J Neurooncol 85:229-230. doi: 10.1007/s11060-007-9403-6
8. Jalali R, Singh P, Menon H et al (2007) Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide. J Neurooncol 85:105-107. doi: 10.1007/s11060-007-9398-z
9. Villano JL, Collins CA, Manasanch EE et al (2006) Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7:436-438. doi: 10.1016/S1470-2045(06)70696-9
10. Hirose Y, Berger MS, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957-1963
11. Gerson SL (2004) MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307. doi: 10.1038/nrc1319
12. Karran P, Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16:833-839. doi: 10.1002/bies.950161110
13. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167-223. doi: 10.1016/S0079-6603(08)60879-X
14. 6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol 37:897-906. doi: 10.1093/jjco/hym132
15. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354. doi: 10.1056/ NEJM200011093431901
16. George JN, Raskob GE, Shah SR et al (1998) Drug-induced thrombocytopenia: A systematic review of published case reports. Ann Intern Med 129:886-890
17. Anon (1989) Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study. Arch Intern Med 149:1036-1040. doi: 10.1001/archinte.149.5.1036
18. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011. doi: 10.1038/ sj.bjc.6600827
19. Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197. doi: 10.1200/ JCO.2007.14.8163